Benzothienopyridines for use as inhibitors of Eg5 kinesin

A combination comprising

• a first active ingredient, which is at least one compound of formula (I*)
• in which
• R1 is 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, or 2-7C-alkyl substituted by R11,
• R11 is —N(R111)R112,
• R111 is hydrogen, or 1-4C-alkyl,
• R112 is hydrogen, or 1-4C-alkyl,
• or R111 and R112 together, and with inclusion of the nitrogen atom to which they are bonded, form a ring Het,
• Het is piperidinyl, morpholinyl, thiomorpholinyl, or pyrrolidinyl,
• R2 is hydrogen, 1-4C-alkyl, halogen, trifluoromethyl, 1-4C-alkoxy, hydroxyl, 1-4C-alkoxy-2-4C-alkoxy, hydroxy-2-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkyl-1-4C-alkoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy,
• R3 is hydrogen, or 1-4C-alkoxy, and
• X is NH, oxygen or sulphur, and
• R4 is 1-4C-alkyl,
• or
• X is sulphur, and
• R4 is hydrogen,
• or
• X is oxygen, and
• R4 is hydrogen,
• or
• (±)-(3aSR,10RS)-10-(3-Hydroxy-phenyl)-2,3a-dimethyl-3a,4,9,10-tetrahydro-2,9,10a-triaza -cyclopenty[b]fluorene-1,3-dione;
• (3aSR,10RS)-10-(3-Hydroxy-phenyl)-2,3a-dimethyl-4,10-dihydro-3aH-9-thia-2,10a-diaza -cyclopenta[b]fluorene-1,3-dione;
• (3aSR,10RS)-2-(2-Dimethylamino-ethyl)-10-(3-hydroxy-phenyl)-3a-methyl-3a,4,9,10-tetrahydro -2,9,10a-triaza-cyclopenty[b]fluorene-1,3-dione;
• or
• (3aSR,10RS)-2-(2-Dimethylamino-ethyl)-10-(3-hydroxy-phenyl)-3a-methyl-4,10-dihydro-3aH-9-thia-2,10a-diaza-cyclopenta[b]fluorene-1,3-dione
• or a salt, stereoisomer or a salt of a stereoisomer thereof;
• and
• a second active ingredient, which is at least one anti-cancer agent selected from the group consisting of chemotherapeutic anti-cancer agents and target-specific anti-cancer agents.